You might also like
ACELYRIN, INC. (Nasdaq: SLRN) is a late-stage clinical biopharmaceutical company focused on developing and commercializing transformative medicines to address unmet medical needs. Headquartered in the Los Angeles area with additional operations in the San Francisco Bay area, the company specializes in identifying and accelerating the development of innovative therapies. ACELYRIN does not currently have any approved products for commercial sale and is primarily engaged in clinical development activities.
- Izokibep - A small protein therapeutic designed to inhibit IL-17A, currently in late-stage clinical trials for hidradenitis suppurativa, psoriatic arthritis, and uveitis, with plans for axial spondyloarthritis.
- Lonigutamab - A monoclonal antibody targeting the IGF-1 receptor, being developed for the treatment of Thyroid Eye Disease (TED).
- SLRN-517 - A monoclonal antibody targeting c-KIT, under development for chronic urticaria.
| Name | Position | External Roles | Short Bio | |
|---|---|---|---|---|
Mina Kim ExecutiveBoard | Chief Executive Officer | None | Mina Kim is the CEO of ACELYRIN, INC. since May 9, 2024. She joined the company in November 2022 as Chief Legal and Administrative Officer. She has been instrumental in advancing the company's pipeline strategy. | View Report → |
Shephard Mpofu Executive | Chief Medical Officer | None | Dr. Mpofu joined Acelyrin in September 2023 as CMO. He has extensive experience in clinical development and was previously CMO of Novartis' Gene Therapy franchise. | |
Beth Seidenberg Board | Director | Managing Director at Westlake Village BioPartners; General Partner at Kleiner Perkins Caufield & Byers; Board Member at Progyny, Inc. and Vera Therapeutics, Inc. | Beth Seidenberg has been a Director at SLRN since October 2020. She is a venture capitalist with a focus on life sciences. | |
Dawn Svoronos Board | Director | Board Member at Adverum Biotechnologies, Xenon Pharmaceuticals Inc., Theratechnologies Inc.; Director at AgNovos Healthcare LLC | Dawn Svoronos has been a Director at SLRN since December 2022. She has a long career in the pharmaceutical industry, including a 23-year tenure at Merck & Co., Inc.. | |
Henry O. Gosebruch Board | Director | President, CEO, and Board Member at Neumora Therapeutics, Inc.; Advisory Board Member at the University of Pennsylvania; Board Member at Aptinyx, Inc. | Henry O. Gosebruch has been a Director at SLRN since March 2023. He has extensive experience in corporate strategy and business development. | |
Lynn Tetrault Board | Director | Chair of the Board at NeoGenomics, Inc.; Director at Rhythm Pharmaceuticals, Inc. | Lynn Tetrault has been a Director at SLRN since December 18, 2023, and serves as Chair of the Compensation Committee. She has extensive experience in human resources and corporate affairs. |
- Given the potential for hearing-related adverse events with anti-IGF-1R agents like lonigutamab, can you elaborate on how your Phase III dosing strategy aims to mitigate these risks, and what thresholds for hearing impairment are acceptable for regulatory approval?
- With biologic-experienced patients included in your izokibep uveitis trial—unlike the VISUAL I study for adalimumab—how might this affect the efficacy outcomes, and how will you interpret the data in the context of these differing patient populations?
- Considering your cash runway projections to mid-2027 exclude new investments in izokibep, what specific criteria will you use to decide whether to advance izokibep into a Phase III uveitis trial, and how would this impact your financial guidance?
- How do you plan to balance further development of izokibep, given the $35.7 million manufacturing credit voucher, with your primary focus on lonigutamab, and what factors would trigger renewed investment in the izokibep program?
- As you plan to extend dosing of lonigutamab to 52 weeks in both active and inactive TED patients, what evidence supports the long-term safety and efficacy over this extended period, and how have regulators responded to this approach compared to standard treatment durations?
Notable M&A activity and strategic investments in the past 3 years.
| Company | Year | Details |
|---|---|---|
ACELYRIN, Inc. (via Alumis Inc.) | 2025 | Alumis Inc. and ACELYRIN, Inc. will merge in an all‑stock transaction, where each ACELYRIN share converts into 0.4274 Alumis shares, resulting in roughly 45% ownership for ACELYRIN stockholders; the merger will create a late‑stage clinical biopharma company with a robust pipeline (including ESK‑001 and lonigutamab) and an anticipated pro forma cash position of about $737 million, subject to customary closing conditions. |
ValenzaBio, Inc. (by SLRN) | 2023 | SLRN acquired ValenzaBio, Inc. via an all‑stock asset acquisition that involved issuing 18,885,731 Class A shares (with additional cash, assumed options, and severance packages), adding strategic assets like lonigutamab and SLRN‑517 to its portfolio focused on autoimmune and inflammatory diseases. |
Recent press releases and 8-K filings for SLRN.
- On May 21, 2025, ACELYRIN completed its merger with Merger Sub, becoming a wholly owned subsidiary of Alumis. Under the transaction, each share of ACELYRIN common stock was converted into 0.4814 shares of Alumis common stock plus cash for any fractional shares.
- The company terminated its 2023 Employee Stock Purchase Plan and requested Nasdaq suspend trading and initiate delisting of its common stock as part of its corporate restructuring.
- ACELYRIN, Inc. held a virtual special meeting on May 13, 2025, where stockholders voted on key proposals related to its merger with Alumis Inc. and associated adjournment measures.
- The merger proposal was approved with 52,943,588 votes for against 41,376,937 votes against, and the adjournment proposal received 47,828,119 votes for, with a planned closing on May 21, 2025.
- ACELYRIN stockholders will receive 0.4814 shares of Alumis common stock per share, resulting in an approximate 48% ownership in the combined company, compared to Alumis’ 52% (referenced in ).
- The investor presentation highlights potential value upside from key upcoming milestones, including a Phase 3 data readout in Q1 2026, with pro forma equity values projected between $6.90 and $8.96 per ACELYRIN share (referenced in ).
- The merger is structured to significantly extend financial runway, supported by a pro forma cash position of approximately $737 million as of 4Q24, ensuring operational funding into 2027 (referenced in ).
- ACELYRIN, Inc. has adopted a limited-duration stockholder rights plan effective immediately, which will expire on March 12, 2026.
- The plan issues one right per share of common stock as of the March 24, 2025 record date, allowing holders to purchase additional shares if an acquiring party exceeds a 10% (or 20% for Schedule 13G reporters) threshold.
- This action is a defensive measure in response to Tang Capital Partners' accumulation of 8.8% of the company’s outstanding stock, aiming to protect shareholder value.